Palvella Therapeutics (NASDAQ:PVLA) Upgraded by Jones Trading to Strong-Buy Rating

Palvella Therapeutics (NASDAQ:PVLA) was upgraded by Jones Trading to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $38.00 target price on shares of Palvella Therapeutics in a research note on Tuesday, February 11th. Cantor Fitzgerald began coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating for the company. TD Cowen started coverage on shares of Palvella Therapeutics in a research report on Wednesday, February 5th. They set a “buy” rating and a $44.00 target price on the stock. Canaccord Genuity Group restated a “buy” rating and issued a $39.00 price target on shares of Palvella Therapeutics in a report on Wednesday, February 26th. Finally, Scotiabank assumed coverage on shares of Palvella Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price target for the company. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $43.20.

Palvella Therapeutics Stock Performance

Shares of Palvella Therapeutics stock opened at $27.27 on Monday. The stock’s 50-day simple moving average is $19.36. Palvella Therapeutics has a 1-year low of $6.20 and a 1-year high of $29.27. The firm has a market cap of $306.00 million, a P/E ratio of -2.25 and a beta of 0.54.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in PVLA. BML Capital Management LLC bought a new stake in shares of Palvella Therapeutics during the fourth quarter worth about $506,000. Geode Capital Management LLC bought a new stake in Palvella Therapeutics during the 4th quarter worth approximately $171,000. ADAR1 Capital Management LLC purchased a new stake in shares of Palvella Therapeutics in the fourth quarter worth approximately $1,736,000. Renaissance Technologies LLC bought a new position in shares of Palvella Therapeutics in the fourth quarter valued at approximately $256,000. Finally, Blue Owl Capital Holdings LP purchased a new position in shares of Palvella Therapeutics during the fourth quarter valued at approximately $3,001,000. 40.11% of the stock is owned by institutional investors.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.